Can new drug combos outsmart PARP resistance in BRCA breast cancer?
NCT ID NCT04090567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding cediranib or ceralasertib to olaparib can overcome resistance in BRCA-mutated advanced breast cancer. About 60 participants with HER2-negative, BRCA-positive tumors that have progressed on prior therapy will receive one of the two drug combinations. The main goal is to see if tumors shrink, with secondary focus on how long progression is delayed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib combined with either cediranib or ceralasertib
- What this could lead to
- If successful, this could offer new treatment options for people with BRCA-mutated advanced breast cancer whose tumors have stopped responding to standard PARP inhibitors.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply to everyone. The drug combinations may cause side effects or fail to shrink tumors in many patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Digital therapy aims to tame the fear that haunts cancer survivors
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?